259 related articles for article (PubMed ID: 31498127)
1. Safety Profile of Opicapone in the Management of Parkinson's Disease.
Lees A; Ferreira JJ; Rocha JF; Rascol O; Poewe W; Gama H; Soares-da-Silva P
J Parkinsons Dis; 2019; 9(4):733-740. PubMed ID: 31498127
[TBL] [Abstract][Full Text] [Related]
2. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
[TBL] [Abstract][Full Text] [Related]
4. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Lees AJ; Ferreira J; Rascol O; Poewe W; Rocha JF; McCrory M; Soares-da-Silva P;
JAMA Neurol; 2017 Feb; 74(2):197-206. PubMed ID: 28027332
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P
Eur J Neurol; 2019 Jul; 26(7):953-960. PubMed ID: 30681754
[TBL] [Abstract][Full Text] [Related]
6. Opicapone: A Review in Parkinson's Disease.
Scott LJ
CNS Drugs; 2021 Jan; 35(1):121-131. PubMed ID: 33428178
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
Kwak N; Park J; Kang HY; Lee MJ; Suh JK; Lee H
J Parkinsons Dis; 2022; 12(3):773-783. PubMed ID: 35180134
[TBL] [Abstract][Full Text] [Related]
8. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
9. The launch of opicapone for Parkinson's disease: negatives versus positives.
Castro Caldas A; Teodoro T; Ferreira JJ
Expert Opin Drug Saf; 2018 Mar; 17(3):331-337. PubMed ID: 29415596
[TBL] [Abstract][Full Text] [Related]
10. Opicapone: A Review in Parkinson's Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1293-1300. PubMed ID: 27498199
[TBL] [Abstract][Full Text] [Related]
11. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
12. Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
Żegleń M; Śladowska K; Kawalec P; Brzostek T
J Comp Eff Res; 2022 Aug; 11(12):889-904. PubMed ID: 35758044
[No Abstract] [Full Text] [Related]
13. Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations.
Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
J Neural Transm (Vienna); 2021 Mar; 128(3):337-344. PubMed ID: 33630140
[TBL] [Abstract][Full Text] [Related]
14. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
Fabbri M; Ferreira JJ; Lees A; Stocchi F; Poewe W; Tolosa E; Rascol O
Mov Disord; 2018 Oct; 33(10):1528-1539. PubMed ID: 30264443
[TBL] [Abstract][Full Text] [Related]
15. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
16. Opicapone for the treatment of Parkinson's disease: a review.
Feldman M; Margolesky J
Int J Neurosci; 2023 May; 133(5):532-543. PubMed ID: 33980110
[No Abstract] [Full Text] [Related]
17. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
Lees AJ; Ferreira J; Rascol O; Reichmann H; Stocchi F; Tolosa E; Poewe W
Expert Rev Neurother; 2017 Jul; 17(7):649-659. PubMed ID: 28580819
[TBL] [Abstract][Full Text] [Related]
18. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
St Onge E; Vanderhoof M; Miller S
Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
[TBL] [Abstract][Full Text] [Related]
19. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
[TBL] [Abstract][Full Text] [Related]
20. [Opicapone for the treatment of Parkinson's disease: real-life data in Spain].
López-Ariztegui N; Mata-Alvarez Santullano M; Tegel I; Almeida F; Sarasa P; Rojo R; Rico-Villademoros F; Abril-Jaramillo J; Bermejo P; Borrue C; Caballol N; Campins-Romeu M; Clavero P; García-Caldentey J; Gómez-Mayordomo V; Labandeira C; Martí-Andrés G; Martínez-Castrillo JC; Martinez-Poles J; Muñoz T; Salom JM; Valderrama-Martín C; Vinagre-Aragón A
Rev Neurol; 2021 Dec; 73(s02):S01-S14. PubMed ID: 34897643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
